BECTON DICKINSON & Q2 FY26 earnings call BDX

Revenue of $4.7B grew 2.6% FX-neutral, with management stressing the breadth: more than 90% of the portfolio grew mid-single digits (~5%). Key growth platforms delivered double-digit growth — biologic drug delivery, Advanced Patient Monitoring, PureWick and Advanced Tissue Regeneration — while oncology, peripheral arterial disease and Rowa pharmacy automation grew mid- to high single digits. Management positioned these as scaling faster than the base and becoming a more meaningful driver of the long-term growth algorithm, with strength spread across multiple platforms and geographies rather than one business.

Adjusted gross margin was 54.7%, down 90 bps YoY, comprising 70 bps of positive productivity/mix offset by 160 bps of tariffs. Adjusted operating margin fell 110 bps to 24.2%, again 160 bps of tariffs plus increased commercial investment in growth areas. Both metrics came in ahead of internal expectations. Management reaffirmed ~25% full-year adjusted operating margin inclusive of tariffs, with the second-half ramp driven by BD Excellence, which delivered ~8% productivity in the quarter.

BD received an FDA warning letter tied to its El Paso, Texas facility making ChloraPrep and PurPrep infection-prevention products, and voluntarily placed those products on U.S. ship hold pending additional final-release testing. The added testing loop mirrors what BD already performs for European-shipped product and is expected to take ~3 weeks, with shipments resuming pending satisfactory results. Management emphasized no patient-safety signals, that it stands behind the products' safety, and that manufacturing continues uninterrupted during the hold. Products sit primarily in the surgical business with some in MDS.

Adjusted EPS of $2.90 excludes approximately $450M of noncash asset impairment charges recorded in the quarter. Following the Life Sciences separation and combination with Waters, BD exited certain activities no longer aligned with the New BD strategy. Management framed the charges as part of simplifying BD, sharpening focus and reallocating resources to the platforms that matter most for long-term value creation. Prior periods were recast to reflect Life Sciences as discontinued operations.

With the stock viewed as substantially undervalued, BD elevated share repurchases to the top capital-allocation priority, returning $2.3B to shareholders in the quarter including $2B of buybacks and $0.3B of dividends, and retired $2.1B of debt. Tuck-in M&A now sits behind buybacks, though management stressed an active but focused funnel and unchanged discipline — only accretive deals that accelerate growth, expand margins and improve ROIC. Year-to-date free cash flow rose sharply to $1.1B on working-capital discipline.

Within MMS, Alaris performed modestly better than expected, gaining ~50 bps of share in the quarter and ~150 bps year-to-date, with the largest competitive funnel in company history and no infusion accounts lost. Infusion sets grew low double digits, aided by an easy fluid-shortage comp and share-gain pull-through. BD is early in launching Pyxis Pro — the first new Pyxis platform in ~20 years and the first AI- and cloud-enabled version — where 75% of first-half wins were competitive conversions. The new BD Incada AI platform will connect Alaris, Pyxis and APM devices into an end-to-end medication-management workflow.

BD Excellence, now deeply embedded, will run over 2,000 Kaizens this year and drove ~8% productivity (matching last year) plus >90% service levels. The manufacturing network has been cut roughly in half to ~50 sites with further reductions underway. This year BD began extending the system into commercial processes (under new Chief Revenue Officer Mike Feld) and R&D, where the first five development programs saw time-to-launch pulled forward^📎 by an average of over 10 months, with more planned in H2.

BioPharma Systems declined 1.8% as continued double-digit Biologics growth, led by GLP-1s, was offset by lower vaccine demand. Management announced two new GLP-1 programs with leading global pharma companies and cited over 80 signed GLP-1 biosimilar deals, some in higher-ASP auto-injectors and pens that carry several times the value of a syringe. Biologics now represent ~55% of BioPharma segment revenue, up from a prior 50%. Management views oral GLP-1s as incremental and complementary, with injectables remaining the category backbone.